Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.71 |
| ▸ | BUB1 | O43683 | 1/20 | 0.70 |
| ▸ | PRKACG | P22612 | 1/20 | 0.70 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.70 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.70 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411695 | 1.00 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3412230 | 0.91 | MAPK14 (0.72) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL31079747 | 0.91 | MAPK14 (0.72) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL27598484 | 0.89 | MAPK14 (0.56) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL30335787 | 0.89 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409775 | 0.89 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL29795179 | 0.88 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3426997 | 0.88 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3411239 | 0.87 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL29593526 | 0.87 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CYP2C9 4736/4885MAPK11 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.